PROMOMED and the Russian Society of Clinical Oncology will join their efforts against cancer

November 14, Moscow. At the XXVIII Russian Oncology Congress that took place in Moscow on November 12-14, the PROMOMED group and the Russian Society of Clinical Oncology (RUSSСO) signed the Memorandum of cooperation and collaboration. For the first time the congress was comprehensively supported by the PROMOMED group. The terms of collaboration were announced at the PROMOMED satellite symposium chaired by the founder of RUSSCO and its board member, Prof. Sergey Tyulandin, doctor of medical science, in Moscow, bringing together experts in oncology and pharmaceutics from Russia and foreign countries.

The signed memorandum implies comprehensive cooperation in the development of the pharmaceutical industry and medicine. The efforts of the parties will be aimed at combating, preventing, diagnosing and treating cancer.

Today, the Russian pharmaceutical industry is applying its best efforts towards achieving technological sovereignty and securing the health of the Russian population. According to the Ministry of Health, the current number of cancer cases is above 4 million, with the annual increase is 600 thousand patients. Countless of various innovative therapies are used to treat malignancies are used in the global practice. It is impossible to implement all of them in full: no national healthcare system in the world can withstand it. Therefore, one should concentrate efforts on creating and utilizing our own technologies in the development of medicines for the treatment of malignancies. This is a requisite to achieving pharmaceutical sovereignty. In this context, the interaction between drug developers and the medical community, scientists and manufacturers is of strategic importance. The synergistic effect of such cooperation will allow us to find new ways to find new solutions in the development of tools for the treatment, therapy, diagnostics, and prevention of cancer”, said Ilya Bardin-Denisov, PROMOMED DM LLC CEO.

RUSSCO and the PROMOMED group agreed to join efforts in the field of scientific and clinical research, improving the professional excellence of specialists, development and introduction of innovative medicines.

“We expect that the cooperation between the professional community and the developer will contribute to the speedy launch of new drugs on the market, which are essential for the treatment of cancer patients. Those medicines will address unmet needs and will be implemented into real clinical practice as soon as possible. We believe that this cooperation is beneficial to all parties: patients, the professional community, developers and manufacturers”, emphasized Sergey Tyulandin, Honored Scientist, chief research associate, antineoplastic medical treatment department #2, federal state budgetary institution N.N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health, RUSSCO board member.

The PROMOMED group offers to the oncology community its own experience which can lay the foundation of educational and research programs, practice guidelines and teaching aids. The cooperation involves comprehensive support in developing and implementing strategies for early diagnosis and prevention of cancer.